{"id":76658,"date":"2026-08-26T12:45:24","date_gmt":"2026-08-26T04:45:24","guid":{"rendered":"https:\/\/flcube.com\/?p=76658"},"modified":"2026-08-26T12:45:24","modified_gmt":"2026-08-26T04:45:24","slug":"fosun-pharma-2026h1-revenue-rises-4-75-to-rmb-20-44-billion-as-innovative-drugs-and-globalization-power-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76658","title":{"rendered":"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2196:HKG\">HKG: 2196<\/a>)<\/strong> announced its interim results for 2026. In the first half of 2026 (<strong>2026H1<\/strong>), the Company recorded <strong>revenue of RMB 20.442 billion<\/strong>, a year\u2011on\u2011year (YOY) increase of <strong>4.75%<\/strong>, while profit attributable to shareholders, net of non\u2011recurring gains and losses, reached <strong>RMB 1.144 billion, up 19.09% YOY<\/strong> \u2014 evidence that innovation and globalization are delivering accelerating earnings quality.<\/p>\n\n\n\n<h2 id=\"h-2026h1-financial-highlights\" class=\"wp-block-heading\">2026H1 Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026H1<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Revenue<\/strong><\/td><td>RMB 20.442B<\/td><td><strong>+4.75%<\/strong><\/td><\/tr><tr><td><strong>Net Profit (ex non\u2011recurring items)<\/strong><\/td><td>RMB 1.144B<\/td><td><strong>+19.09%<\/strong><\/td><\/tr><tr><td><strong>Innovative Drug Revenue<\/strong><\/td><td>RMB 4.911B<\/td><td><strong>+13.84%<\/strong> (33.21% of pharma segment)<\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>RMB 3.247B<\/td><td><strong>+25.66%<\/strong><\/td><\/tr><tr><td><strong>Overseas Revenue (ex\u2011Mainland)<\/strong><\/td><td>RMB 6.379B<\/td><td><strong>+16.45%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-innovation-engine\" class=\"wp-block-heading\">Innovation Engine<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Focus:<\/strong> 81.61% of total R&amp;D investment is directed at innovative drugs, concentrated on pipelines including <strong>HLX43, HLX22, GR1803, FXR0906<\/strong>, next\u2011generation small molecules, radiopharmaceuticals, and other cutting\u2011edge technology platforms.<\/li>\n\n\n\n<li><strong>Approval Momentum:<\/strong><strong>20 indications across 7 innovative drugs<\/strong> were approved domestically and overseas during the period, marking a phase of intensive approvals and value realisation:\n<ul class=\"wp-block-list\">\n<li><strong>Hansizhuang (serplulimab):<\/strong> New China approval in perioperative gastric cancer, plus three additional EU first\u2011line approvals in squamous NSCLC, esophageal squamous\u2011cell carcinoma, and non\u2011squamous NSCLC<\/li>\n\n\n\n<li><strong>Hanbeiyou (pertuzumab):<\/strong> Successive marketing approvals in the EU and China<\/li>\n\n\n\n<li><strong>Fumaining (luvometinib):<\/strong> New indication for relapsed\/refractory Langerhans\u2011cell histiocytosis (LCH) in patients aged two and older following systemic therapy<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-globalization-engine\" class=\"wp-block-heading\">Globalization Engine<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>International Revenue:<\/strong> Business revenue from regions outside Chinese mainland and other countries reached <strong>RMB 6.379 billion, up 16.45% YOY<\/strong>.<\/li>\n\n\n\n<li><strong>Out\u2011Licensing:<\/strong> Subsidiary <strong>Shanghai Henlius<\/strong> entered strategic partnerships with <strong>Eisai<\/strong> and <strong>Abbott<\/strong> to out\u2011license serplulimab, extending the franchise&#8217;s global footprint.<\/li>\n\n\n\n<li><strong>Alzheimer&#8217;s Option:<\/strong> <strong>Fosun Pharma<\/strong> signed a <strong>global exclusive option agreement<\/strong> with <strong>AriBio<\/strong> for <strong>AR1001<\/strong>, an investigational Alzheimer&#8217;s disease drug, with plans to expand rights to key markets including the US, Europe, and Japan.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Earnings Quality:<\/strong> Profit growth of 19.09% versus revenue growth of 4.75% signals a favourable mix shift toward higher\u2011margin innovative drugs, now 33.21% of pharmaceutical segment revenue.<\/li>\n\n\n\n<li><strong>Pipeline Depth:<\/strong> The 25.66% step\u2011up in R&amp;D spend \u2014 overwhelmingly innovation\u2011focused \u2014 positions <strong>Fosun Pharma<\/strong> for a sustained approval cycle across oncology, rare disease, and next\u2011generation modalities.<\/li>\n\n\n\n<li><strong>Global Monetisation:<\/strong> Overseas growth of 16.45% plus high\u2011profile deals with Eisai, Abbott, and AriBio demonstrate that globalization is transitioning from strategy to measurable earnings contribution.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding revenue trends, pipeline milestones, and international expansion for Fosun Pharma. Actual results may differ due to risks including regulatory approvals, partnership execution, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082502119.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082502119.\"><\/object><a id=\"wp-block-file--media-09a2badd-53c4-436f-9a48-bc8bcc98a1fc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082502119.pdf\">2026082502119<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082502119.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-09a2badd-53c4-436f-9a48-bc8bcc98a1fc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its interim results for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76662,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,4908],"tags":[27,159,893,892],"class_list":["post-76658","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-pic","tag-finanical-reports","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its interim results for 2026. In the first half of 2026 (2026H1), the Company recorded revenue of RMB 20.442 billion, a year\u2011on\u2011year (YOY) increase of 4.75%, while profit attributable to shareholders, net of non\u2011recurring gains and losses, reached RMB 1.144 billion, up 19.09% YOY \u2014 evidence that innovation and globalization are delivering accelerating earnings quality.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76658\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth\" \/>\n<meta property=\"og:description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its interim results for 2026. In the first half of 2026 (2026H1), the Company recorded revenue of RMB 20.442 billion, a year\u2011on\u2011year (YOY) increase of 4.75%, while profit attributable to shareholders, net of non\u2011recurring gains and losses, reached RMB 1.144 billion, up 19.09% YOY \u2014 evidence that innovation and globalization are delivering accelerating earnings quality.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76658\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-26T04:45:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2604.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76658#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76658\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth\",\"datePublished\":\"2026-08-26T04:45:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76658\"},\"wordCount\":427,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76658#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2604.webp\",\"keywords\":[\"Finanical Reports\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76658#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76658\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76658\",\"name\":\"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76658#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76658#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2604.webp\",\"datePublished\":\"2026-08-26T04:45:24+00:00\",\"description\":\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its interim results for 2026. In the first half of 2026 (2026H1), the Company recorded revenue of RMB 20.442 billion, a year\u2011on\u2011year (YOY) increase of 4.75%, while profit attributable to shareholders, net of non\u2011recurring gains and losses, reached RMB 1.144 billion, up 19.09% YOY \u2014 evidence that innovation and globalization are delivering accelerating earnings quality.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76658#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76658\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76658#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2604.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2604.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76658#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its interim results for 2026. In the first half of 2026 (2026H1), the Company recorded revenue of RMB 20.442 billion, a year\u2011on\u2011year (YOY) increase of 4.75%, while profit attributable to shareholders, net of non\u2011recurring gains and losses, reached RMB 1.144 billion, up 19.09% YOY \u2014 evidence that innovation and globalization are delivering accelerating earnings quality.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76658","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth","og_description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its interim results for 2026. In the first half of 2026 (2026H1), the Company recorded revenue of RMB 20.442 billion, a year\u2011on\u2011year (YOY) increase of 4.75%, while profit attributable to shareholders, net of non\u2011recurring gains and losses, reached RMB 1.144 billion, up 19.09% YOY \u2014 evidence that innovation and globalization are delivering accelerating earnings quality.","og_url":"https:\/\/flcube.com\/?p=76658","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-26T04:45:24+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2604.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76658#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76658"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth","datePublished":"2026-08-26T04:45:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76658"},"wordCount":427,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76658#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2604.webp","keywords":["Finanical Reports","Fosun Pharmaceutical","HKG: 2196","SHA: 600196"],"articleSection":["Company","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76658#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76658","url":"https:\/\/flcube.com\/?p=76658","name":"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76658#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76658#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2604.webp","datePublished":"2026-08-26T04:45:24+00:00","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its interim results for 2026. In the first half of 2026 (2026H1), the Company recorded revenue of RMB 20.442 billion, a year\u2011on\u2011year (YOY) increase of 4.75%, while profit attributable to shareholders, net of non\u2011recurring gains and losses, reached RMB 1.144 billion, up 19.09% YOY \u2014 evidence that innovation and globalization are delivering accelerating earnings quality.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76658#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76658"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76658#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2604.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2604.webp","width":1080,"height":608,"caption":"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76658#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2604.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76658"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76658\/revisions"}],"predecessor-version":[{"id":76663,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76658\/revisions\/76663"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76662"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}